Recently, a promising approach has involved oridonin-derivatives, which act as pro-oxidants upon activation by NQO1, which is abundantly expressed in CLL cells overexpressing the orphan receptor ROR1. Here, ROR1 is linked to B-cell chronic lymphocytic leukemia.